ClinVar Miner

Submissions for variant NM_002225.5(IVD):c.550+1G>A

gnomAD frequency: 0.00007  dbSNP: rs377147994
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000413513 SCV000490570 pathogenic not provided 2023-10-24 criteria provided, single submitter clinical testing Observed in patient with inborn error of metabolism in published literature; however, no further clinical information was provided (PMID: 32778825); Canonical splice site variant predicted to result in a null allele in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Also known as c.550+1 G>A; This variant is associated with the following publications: (PMID: 16602101, 16199547, 32778825)
Baylor Genetics RCV000984189 SCV001163384 pathogenic Isovaleryl-CoA dehydrogenase deficiency criteria provided, single submitter clinical testing
Invitae RCV000984189 SCV001222259 pathogenic Isovaleryl-CoA dehydrogenase deficiency 2024-01-13 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 5 of the IVD gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in IVD are known to be pathogenic (PMID: 16602101). This variant is present in population databases (rs377147994, gnomAD 0.007%). Disruption of this splice site has been observed in individual(s) with clinical features of isovaleric acidemia (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 372389). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
New York Genome Center RCV000984189 SCV001480433 likely pathogenic Isovaleryl-CoA dehydrogenase deficiency 2020-05-26 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000984189 SCV002598727 likely pathogenic Isovaleryl-CoA dehydrogenase deficiency 2022-09-29 criteria provided, single submitter clinical testing Variant summary: IVD c.550+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes the canonical 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 8e-06 in 251444 control chromosomes (gnomAD). To our knowledge c.550+1G>A has not been reported in the literature in individuals affected with Isovaleryl-CoA Dehydrogenase Deficiency and no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Ambry Genetics RCV002523909 SCV003644991 uncertain significance Inborn genetic diseases 2021-07-14 criteria provided, single submitter clinical testing The c.559+1G>A intronic alteration consists of a G to A substitution one nucleotide after exon 5 of the IVD gene. Alterations that disrupt the canonical splice donor site are typically deleterious in nature (Richards, 2015). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
PreventionGenetics, part of Exact Sciences RCV003401395 SCV004120568 likely pathogenic IVD-related disorder 2022-11-29 criteria provided, single submitter clinical testing The IVD c.559+1G>A variant is predicted to disrupt the GT donor site and interfere with normal splicing. To our knowledge this variant has not been reported in the literature. This variant is reported in 0.0058% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/15-40703553-G-A). Variants that disrupt the consensus splice donor site in IVD are expected to be pathogenic. This variant is interpreted as pathogenic.
Counsyl RCV000984189 SCV001132236 likely pathogenic Isovaleryl-CoA dehydrogenase deficiency 2014-01-02 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.